[go: up one dir, main page]

NO20052363L - Interferon-alfa polypeptider og konjugater - Google Patents

Interferon-alfa polypeptider og konjugater

Info

Publication number
NO20052363L
NO20052363L NO20052363A NO20052363A NO20052363L NO 20052363 L NO20052363 L NO 20052363L NO 20052363 A NO20052363 A NO 20052363A NO 20052363 A NO20052363 A NO 20052363A NO 20052363 L NO20052363 L NO 20052363L
Authority
NO
Norway
Prior art keywords
conjugates
polypeptides
nucleic acids
interferon
alpha polypeptides
Prior art date
Application number
NO20052363A
Other languages
English (en)
Other versions
NO20052363D0 (no
Inventor
Torben Lauesgaard Nissen
Phillip A Patten
Sridhar Govindarajan
Sridhar Viswanathan
Original Assignee
Maxygen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Inc filed Critical Maxygen Inc
Publication of NO20052363D0 publication Critical patent/NO20052363D0/no
Publication of NO20052363L publication Critical patent/NO20052363L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SAMMENDRAG Foreliggende oppfinnelse tilveiebringer interferon-alfa polypeptider og konjugater og nukleinsyrer som koder for polypeptidene. Oppfinnelsen omfatter også sammensetninger omfattende disse polypeptidene, konjugatene og nukleinsyrene; celler som inneholder eller som uttrykker polypeptidene, konjugatene og nukleinsyrene; fremgangsmåter for fremstilling av polypeptidene, konjugatene og nukleinsyrene; og metoder for anvendelse av polypeptidene, konjugatene og nukleinsyrene.
NO20052363A 2002-11-18 2005-05-12 Interferon-alfa polypeptider og konjugater NO20052363L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42761202P 2002-11-18 2002-11-18
US50256003P 2003-09-12 2003-09-12
PCT/US2003/036682 WO2004046365A2 (en) 2002-11-18 2003-11-17 Interferon-alpha polypeptides and conjugates

Publications (2)

Publication Number Publication Date
NO20052363D0 NO20052363D0 (no) 2005-05-12
NO20052363L true NO20052363L (no) 2005-08-08

Family

ID=32329174

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052363A NO20052363L (no) 2002-11-18 2005-05-12 Interferon-alfa polypeptider og konjugater

Country Status (13)

Country Link
US (1) US20040219131A1 (no)
EP (1) EP1565205A4 (no)
JP (1) JP2006506097A (no)
KR (1) KR20050086498A (no)
AU (1) AU2003297285A1 (no)
BR (1) BR0316324A (no)
CA (1) CA2504267A1 (no)
IL (1) IL168049A0 (no)
MX (1) MXPA05005263A (no)
NO (1) NO20052363L (no)
NZ (1) NZ540043A (no)
RU (1) RU2005118998A (no)
WO (1) WO2004046365A2 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1141275B1 (en) 1999-01-05 2009-08-12 Trustees Of Boston University Improved nucleic acid cloning
US7435562B2 (en) 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
US7959910B2 (en) 2000-07-31 2011-06-14 Biolex Therapeutics, Inc. C-terminally truncated interferon alpha variants
US7611700B2 (en) * 2002-09-09 2009-11-03 Hanall Pharmaceuticals, Co., Ltd. Protease resistant modified interferon alpha polypeptides
CA2511815A1 (en) * 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
WO2004060299A2 (en) 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
WO2004076474A2 (en) * 2003-02-26 2004-09-10 Intermune, Inc. Polyethylene glycol modified interferon compositions and methods of use thereof
JP5015608B2 (ja) 2004-01-21 2012-08-29 ネクター セラピューティクス プロピオン酸末端ポリマーの調製方法
US7318918B2 (en) * 2004-05-19 2008-01-15 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
JP2008509889A (ja) * 2004-06-30 2008-04-03 イージェン コーポレーション ペグ化インターフェロンα−１ｂ
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
CA2590245A1 (en) 2004-11-11 2006-05-18 Modular Genetics, Inc. Ladder assembly and system for generating diversity
US9931413B2 (en) * 2005-04-06 2018-04-03 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
US20070054360A1 (en) 2005-05-12 2007-03-08 Zeren Gao Compositions and methods for modulating immune responses
AU2006299901A1 (en) * 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
KR101470472B1 (ko) * 2006-09-14 2014-12-09 메드제닉스 메디칼 이스라엘 리미티드 장기 지속형 약물 제형
US9127084B2 (en) 2006-09-14 2015-09-08 Medgenics Medical Israel Ltd. Long lasting drug formulations
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
CN1970572A (zh) * 2006-12-21 2007-05-30 北京三元基因工程有限公司 干扰素α突变体及其聚乙二醇衍生物
US11535673B2 (en) * 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
US20130225789A1 (en) * 2012-02-29 2013-08-29 Yi Sun Polyethylene Glycol Having Hetero Multiple Functional Groups
US20250145680A1 (en) * 2021-08-18 2025-05-08 Remd Biotherapeutics, Inc. Novel interferon variants and bifunctional fusion molecules thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610830B1 (en) * 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4801685A (en) * 1981-08-14 1989-01-31 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L
US4678751A (en) * 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
IE54592B1 (en) * 1982-03-08 1989-12-06 Genentech Inc Anumal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and espression vehicles containing such sequences and cells transformed thereby
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
EP0205404B1 (en) * 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
US5574138A (en) * 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US6335160B1 (en) * 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
ATE369384T1 (de) * 1999-05-19 2007-08-15 Emd Lexigen Res Ct Corp Expression und export von interferon-alpha proteinen als fc fusionsproteine
AU8001300A (en) * 1999-10-07 2001-05-10 Maxygen, Inc. Ifn-alpha homologues
US20020025304A1 (en) * 2000-06-16 2002-02-28 Croze Edward M. Novel interferon for the treatment of multiple sclerosis
WO2002044197A2 (en) * 2000-12-01 2002-06-06 Fish Eleanor N Cytokine receptor binding peptides
RU2005118752A (ru) * 2002-11-15 2006-02-10 Ф.Хоффманн-Ля Рош Аг (Ch) Позиционные изомеры пэгилированного интерферона l-2а (конъюгата пэг-ifn-l-2а)

Also Published As

Publication number Publication date
RU2005118998A (ru) 2006-01-27
WO2004046365A3 (en) 2004-09-02
US20040219131A1 (en) 2004-11-04
EP1565205A2 (en) 2005-08-24
NZ540043A (en) 2007-11-30
KR20050086498A (ko) 2005-08-30
AU2003297285A1 (en) 2004-06-15
BR0316324A (pt) 2005-09-27
CA2504267A1 (en) 2004-06-03
NO20052363D0 (no) 2005-05-12
EP1565205A4 (en) 2006-07-05
MXPA05005263A (es) 2005-07-25
IL168049A0 (en) 2009-02-11
JP2006506097A (ja) 2006-02-23
WO2004046365A2 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
NO20065084L (no) Interferon-alfa polypeptider og konjugater
NO20052363L (no) Interferon-alfa polypeptider og konjugater
WO2006083276A3 (en) Interferon-alpha polypeptides and conjugates
ATE353955T1 (de) Durch zelloberflächenmoleküle induzierte makrophagenaktivierung
DK1516053T3 (da) Xylanaser, nucleinsyrer, som koder herfor, og fremgangsmåder til at fremstille og benytte disse
DK1131444T3 (da) Polypeptider med lysophospholipase aktivitet og nucleinsyre som koder for disse
DK1409459T3 (da) ECL mærker, som har forbedrede, non-specifikke bindingsegenskaber, fremgangsmåder til anvendelse deraf, og kits indeholdende samme.
EP1578930A4 (en) CNGH0004 POLYPEPTIDES, ANTIBODIES, COMPOSITIONS, METHODS AND USES
NO20005224L (no) BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse
WO2004061080A3 (en) Stress-related polypeptides and uses therefor
WO2004029219A3 (en) Cell-based rna interference and related methods and compositions
WO2004062475A3 (en) Fluorescent assays for protein kinases
WO2002002783A3 (en) Expression vectors
WO1996034107A3 (en) Antiviral proteins, dna coding sequences therefor, and uses thereof
IL185142A0 (en) Lentiviral packaging constructs
NO20043564L (no) Follistatindomene som inneholder proteiner
WO2004061122A3 (en) Cell proliferation-related polypeptides and uses therefor
NO910982L (no) Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller.
WO2007044083A3 (en) Evolved interferon-alpha polypeptides
DK1082423T3 (da) Cyclin E2-gener og -proteiner
WO2002036627A3 (en) Interferons, uses and compositions related thereto
IT1293978B1 (it) Vasca di fermentazione, particolarmente per la vinificazione in rosso.
DK1438417T3 (da) Phytase-enzymer, nukleinsyresekvenser, der koder for fytase-enzymer ogvektorer og værtsceller, der inkorporerer disse
WO2003062453A3 (en) Polycystic kidney disease nucleic acids and proteins
AU2002365269A8 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application